Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
Valhalla, NY
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
Valhalla, NY
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
mi
from
Melbourne,
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
mi
from
Melbourne,
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
Union Hospital of Cecil County
mi
from
Elkton MD, MD
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
Union Hospital of Cecil County
mi
from
Elkton MD, MD
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  8/11/2016
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 8/11/2016
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
Status: Enrolling
Updated:  8/18/2016
Riley Children's Hospital
mi
from
Indianapolis, IN
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
Status: Enrolling
Updated: 8/18/2016
Riley Children's Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
Status: Enrolling
Updated:  8/18/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
Status: Enrolling
Updated: 8/18/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy
The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy
Status: Enrolling
Updated:  9/17/2016
Women and Infants Hospital, Program in Women's Oncology
mi
from
Providence, RI
The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy
The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy
Status: Enrolling
Updated: 9/17/2016
Women and Infants Hospital, Program in Women's Oncology
mi
from
Providence, RI
Click here to add this to my saved trials
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated:  11/17/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated: 11/17/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated:  11/17/2016
Univeristy of California at Davis Medical Center
mi
from
Sacramento, CA
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated: 11/17/2016
Univeristy of California at Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated:  11/17/2016
Stanford University School of Medicine
mi
from
Stanford, CA
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated: 11/17/2016
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated:  11/17/2016
West Virginia University Hospital
mi
from
Morgantown, WV
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated: 11/17/2016
West Virginia University Hospital
mi
from
Morgantown, WV
Click here to add this to my saved trials
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated:  11/17/2016
Kaiser Permanente Northern California
mi
from
Hayard, CA
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling
Updated: 11/17/2016
Kaiser Permanente Northern California
mi
from
Hayard, CA
Click here to add this to my saved trials
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated:  11/22/2016
Novo Nordisk Investigational Site
mi
from
Berkeley, CA
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated: 11/22/2016
Novo Nordisk Investigational Site
mi
from
Berkeley, CA
Click here to add this to my saved trials
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated:  11/22/2016
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated: 11/22/2016
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated:  11/22/2016
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated: 11/22/2016
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated:  11/22/2016
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated: 11/22/2016
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated:  11/22/2016
Novo Nordisk Investigational Site
mi
from
Århus N,
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated: 11/22/2016
Novo Nordisk Investigational Site
mi
from
Århus N,
Click here to add this to my saved trials
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
A Pilot Study of Thalidomide to Overcome Lenalidomide Resistance in Patients Suffering Biochemical Progression on Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Status: Enrolling
Updated:  11/23/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
A Pilot Study of Thalidomide to Overcome Lenalidomide Resistance in Patients Suffering Biochemical Progression on Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Status: Enrolling
Updated: 11/23/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
Pilot Study of Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute Graft Versus Host Disease in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  11/29/2016
Yale University School of Medicine
mi
from
New Haven, CT
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
Pilot Study of Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute Graft Versus Host Disease in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 11/29/2016
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated:  11/30/2016
Cleveland Clinic Myeloma Program
mi
from
Cleveland, OH
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated: 11/30/2016
Cleveland Clinic Myeloma Program
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions
Research Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions
Status: Enrolling
Updated:  12/1/2016
NYU Center for Biomedical Imaging
mi
from
New York, NY
Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions
Research Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions
Status: Enrolling
Updated: 12/1/2016
NYU Center for Biomedical Imaging
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
A Phase I/II Trial Of DLI And Activated DLI (ADLI) Followed By Either Repetitive Dosing Of ADLI Or Dose Escalated ADLI For Patients With Relapse After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  12/1/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
A Phase I/II Trial Of DLI And Activated DLI (ADLI) Followed By Either Repetitive Dosing Of ADLI Or Dose Escalated ADLI For Patients With Relapse After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 12/1/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
University of Florida
mi
from
Gainesville, FL
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
University of Chicago Medical Center
mi
from
Chicago, IL
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Kansas University Medical Center
mi
from
Westwood, KA
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Kansas University Medical Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
The Mayo Clinic
mi
from
Rochester, MN
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Kansas City VA Medical Center/University of Kansas Medical Center
mi
from
Kansas City, MO
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Kansas City VA Medical Center/University of Kansas Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Institute for Translational Oncology Research IRB
mi
from
Greenville, NC
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Institute for Translational Oncology Research IRB
mi
from
Greenville, NC
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Gabrail Cancer Center
mi
from
Canton, OH
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Texas Oncology Cancer Care
mi
from
Austin, TX
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Texas Oncology Cancer Care
mi
from
Austin, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
HOAST
mi
from
San Antonio, TX
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
HOAST
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated:  12/5/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Status: Enrolling
Updated: 12/5/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials